Status:

COMPLETED

To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.

Lead Sponsor:

Pfizer

Conditions:

Seizure Disorder, Partial

Eligibility:

All Genders

12+ years

Phase:

PHASE3

Brief Summary

To evaluate the long-term safety and tolerability of pregabalin in patients with partial seizures.

Eligibility Criteria

Inclusion

  • Must have met the inclusion criteria for preceding double-blind study
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion

  • Cannot have absence seizures

Key Trial Info

Start Date :

November 1 1999

Trial Type :

INTERVENTIONAL

End Date :

July 1 2005

Estimated Enrollment :

750 Patients enrolled

Trial Details

Trial ID

NCT00141336

Start Date

November 1 1999

End Date

July 1 2005

Last Update

January 1 2007

Active Locations (103)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 26 (103 locations)

1

Pfizer Investigational Site

Phoenix, Arizona, United States, 85013

2

Pfizer Investigational Site

Tucson, Arizona, United States, 85724

3

Pfizer Investigational Site

Bakersfield, California, United States, 93301

4

Pfizer Investigational Site

Berkeley, California, United States, 94705